LLLeon G. Leanse

Leon G. Leanse

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leon G. Leanse has a total of 55 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Editorial: Probiotics and bioactive agents in modulating harmful oral biofilms

    by Leon G. G Leanse, Alessandra Nara de Souza Rastelli, Asad U. U Khan, George Grant

    Oral disorders: Oral biofilms harbor pathogenic bacteria, viruses, and mycobionts that contribute to major oral diseases, including dental caries, periodontitis, and oral cancers. Increasing evidence, particularly in oral oncology, indicates that disease outcomes are shaped not only by pathogenic members but also by commensal microbes that can curb or outcompete deleterious species. Accordingly, alongside antimicrobial strategies aimed at disrupting pathogenic biofilms, approaches that selectively enhance beneficial microbial populations may represent effective complementary interventions for the management of biofilm-associated oral diseases (Di Pierro et al., Lv et al., Lasica et al., Perez-Losada et al., Popowski et al., Glavina et al, 2026., Chiscuzzu et al., 2025., Foroughi et al., 2025., Govindarajan et al., 2025., Priya et al., 2025., Baker et al., 2024).Lasica et al. provide a comprehensive review of the inflammatory etiology of periodontitis that results in progressive damage to gingival tissues, periodontal ligaments, cementum, and alveolar bone, ultimately leading to tooth loosening and loss. Beyond oral pathology, periodontitis is associated with systemic, cerebral, and reproductive disorders. Conventional management approaches, including oral hygiene improvement, mechanical plaque removal, and antimicrobial therapy, remain effective in reducing pathogen burden; however, rising antibiotic resistance [microbes within biofilms may be up to 1,000 times more resistant to antibiotics than their free counterparts] and the failure of standard techniques to fully eliminate the deleterious microbes substantially limit their long-term efficacy. Alternative antimicrobial strategies, such as bacteriophage therapy and bacteriotherapy, have therefore gained attention. Bacteriophages can selectively inhibit oral pathogens, but their clinical application remains constrained by limited phage availability. Predatory Gram-negative bacteria, including Bdellovibrio and related organisms (Salah et al., 2025), have demonstrated the ability to reduce key periodontal pathogens (Aggregatibacter actinomycetemcomitans and F. nucleatum) in biofilm models, promote beneficial microbial communities, and exhibit protective effects in pre-clinical animal models. Further research is required to elucidate their mechanisms of action and clinical potential.Oral infections extend beyond epithelial and dental surfaces and represent a major challenge in oral and maxillofacial surgery. Popowski et al. and Choi & Hong (2026) report that pathogencontaining biofilms associated with local tissues and prosthetic materials, which are often highly susceptible to bacterial colonization, contribute to adverse clinical outcomes, including postoperative infections, delayed healing, impaired prosthetic integration, and surgical failure. Autogenous bone remains the preferred grafting material, but its limited availability has increased reliance on xenogeneic and alloplastic substitutes, which are susceptible to microbial colonization and require careful control. Emerging antimicrobial biomaterials, including silverand strontium-doped hydroxyapatite, copper-and zinc-enriched bioglasses, and chitosan-based calcium phosphate scaffolds, show promise by coupling osteogenic potential with biofilm suppression. Nevertheless, strict infection control measures, such as preoperative antiseptic rinses, single-dose antibiotic prophylaxis, and meticulous surgical techniques, remain critical for minimizing microbial risk and ensuring clinical success.Oral biofilm pathogens, including P. gingivalis and F. nucleatum, are increasingly linked to the risk, incidence, and severity of multiple systemic conditions. These include respiratory diseases, type 2 diabetes mellitus, cardiovascular disease, rheumatoid arthritis, bone disorders, hepatic and metabolic dysfunctions, inflammatory bowel diseases, and both intestinal and systemic cancers. These disorders may arise directly via microbial translocation to distal tissues, or indirectly through the systemic dissemination of virulence factors and microbial metabolites. In addition, oral microbes or their metabolic products may reshape the gastrointestinal microbiome and metabolome (Lasica et al., Perez-Losada et al., Glavina et al., 2026., Bruno et al., 2025., Harrandah, 2025., Hu et al., 2025., Kumar and Tyagi, 2025., Kurtzmann et al., 2025a., Kurtzmann et al., 2025b., Nayak et al., 2025., Zhang & Zhang., 2025., Baker et al., 2024).Pérez-Losada et al. demonstrated that oral dysbiosis is associated with allergic rhinitis (AR) and its progression to asthma (ARAS). Patients with AR or ARAS showed increased abundance of Fusobacteriota and Pseudomonadota, along with reduced abundance of Actinobacteriota and Bacillota. At the genus level, Fusobacterium, Gemella, Haemophilus, Leptotrichia, Neisseria, Porphyromonas, and Prevotella were enriched, whereas Actinomyces, Streptococcus, and Veillonella were depleted. Functional analyses indicated upregulation of metabolic pathways linked to allergic sensitization, airway inflammation, and immune responses, supporting oral dysbiosis as a contributory factor in AR onset and progression to ARAS.Akkermansia muciniphila, traditionally recognized as an intestinal commensal, is also detectable in saliva and has been shown to suppress oral inflammation and inhibit periodontal pathogens, including P. gingivalis and F. nucleatum (Anderson et al., 2024). Recent in vivo research by Zhang et al. demonstrates that patients with severe periodontitis exhibit marked gut dysbiosis, characterized by elevated pathogenic taxa and reduced levels of beneficial microbes, such as A. muciniphila. The abundance of A. muciniphila was partially restored in patients following conventional periodontal therapy. In a murine model of periodontitis, which displayed inflammation and compromised intestinal barrier integrity, fecal levels of A. muciniphila were also greatly reduced....

  • Blue Light Compromises Bacterial β‐Lactamases Activity to Overcome β‐Lactam Resistance

    by Carolina dos Anjos, Yin Wang, Que Chi Truong‐Bolduc, Paul K. Bolduc, Matthew Liu, David C. Hooper, R. Rox Anderson, Tianhong Dai, Leon G. Leanse

    Objective: In this study, we evaluated the effectiveness of antimicrobial blue light (aBL; 410 nm wavelength) against β‐lactamase‐carrying bacteria and the effect of aBL on the activity of β‐lactamases.Methods: Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae strains carrying β‐lactamases as well as a purified β‐lactamase enzymes were studied. β‐lactamase activity was assessed using a chromogenic cephalosporin hydrolysis assay. Additionally, we evaluated the role of porphyrins in the photoreaction, as well as protein degradation by sodium dodecyl‐sulfate polyacrylamide gel electrophoresis (SDS‐PAGE). Finally, we investigated the bactericidal effect of combined aBL‐ceftazidime exposure against a metallo‐β‐lactamase expressing P. aeruginosa strain.Results: Our study demonstrated that aBL effectively killed β‐lactamase‐producing bacteria and reduced β‐lactamase activity. After an aBL exposure of 1.52 J/cm2, a 50% reduction in enzymatic activity was observed in P. aeruginosa. Additionally, we found a 40% decrease in the photoreaction activity of porphyrins following an aBL exposure of 64.8 J/cm2. We also revealed that aBL reduced β‐lactamase activity via protein degradation (after 136.4 J/cm2). Additionally, aBL markedly improved the bactericidal effect of ceftazidime (by >4‐log10) in the metallo‐β‐lactamase P. aeruginosa strain.Conclusion: Our results provide evidence that aBL compromises bacterial β‐lactamase activity, offering a potential approach to overcome β‐lactam resistance in bacteria.


  • Open Access

    Blue Light Potentiates Antibiotics in Bacteria via Parallel Pathways of Hydroxyl Radical Production and Enhanced Antibiotic Uptake

    by Leon G. Leanse, Carolina dos Anjos, Kylie Ryan Kaler, Jie Hui, Jeffrey M. Boyd, David C. Hooper, R. Rox Anderson, Tianhong Dai

    In the age of antimicrobial resistance, the urgency by which novel therapeutic approaches need to be introduced into the clinical pipeline has reached critical levels. Antimicrobial blue light (aBL), as an alternative approach, has demonstrated promise as a stand‐alone therapeutic method, albeit with a limited window of antimicrobial activity. Work by others indicates that treatment with antibiotics increases the production of reactive oxygen species (ROS) which may, in part, contribute to the bactericidal effects of antibiotics. These findings suggest that there may be potential for synergistic interactions with aBL, that similarly generates ROS. Therefore, in this study, the mechanism of aBL is investigated, and the potential for aBL to synergistically promote antibiotic activity is similarly evaluated. Furthermore, the translatability of using aBL and chloramphenicol in combination within a mouse model of Acinetobacter baumanii burn infection is assessed. It is concluded that porphyrins and hydroxyl radicals driven by “free iron” are paramount to the effectiveness of aBL; and aBL is effective at promoting multiple antibiotics in different multidrug‐resistant bacteria. Moreover, rROS up‐regulation, and promoted antibiotic uptake are observed during aBL+antibiotic exposure. Lastly, aBL combined with chloramphenicol appears to be both effective and safe for the treatment of A. baumannii burn infection. In conclusion, aBL may be a useful adjunct therapy to antibiotics to potentiate their action.


  • Open Access

    Antimicrobial Resistance: Is There a ‘Light’ at the End of the Tunnel?

    by Leon G. Leanse, Sanjay Marasini, Carolina dos Anjos, Tianhong Dai

    In recent years, with the increases in microorganisms that express a multitude of antimicrobial resistance (AMR) mechanisms, the threat of antimicrobial resistance in the global population has reached critical levels. The introduction of the COVID-19 pandemic has further contributed to the influx of infections caused by multidrug-resistant organisms (MDROs), which has placed significant pressure on healthcare systems. For over a century, the potential for light-based approaches targeted at combatting both cancer and infectious diseases has been proposed. They offer effective killing of microbial pathogens, regardless of AMR status, and have not typically been associated with high propensities of resistance development. To that end, the goal of this review is to describe the different mechanisms that drive AMR, including intrinsic, phenotypic, and acquired resistance mechanisms. Additionally, the different light-based approaches, including antimicrobial photodynamic therapy (aPDT), antimicrobial blue light (aBL), and ultraviolet (UV) light, will be discussed as potential alternatives or adjunct therapies with conventional antimicrobials. Lastly, we will evaluate the feasibility and requirements associated with integration of light-based approaches into the clinical pipeline.


  • Open Access

    Managing Corneal Infections: Out with the old, in with the new?

    by Sanjay Marasini, Jennifer P. Craig, Simon J. Dean, Leon G. Leanse

    There have been multiple reports of eye infections caused by antibiotic-resistant bacteria, with increasing evidence of ineffective treatment outcomes from existing therapies. With respect to corneal infections, the most commonly used antibiotics (fluoroquinolones, aminoglycosides, and cephalosporines) are demonstrating reduced efficacy against bacterial keratitis isolates. While traditional methods are losing efficacy, several novel technologies are under investigation, including light-based anti-infective technology with or without chemical substrates, phage therapy, and probiotics. Many of these methods show non-selective antimicrobial activity with potential development as broad-spectrum antimicrobial agents. Multiple preclinical studies and a limited number of clinical case studies have confirmed the efficacy of some of these novel methods. However, given the rapid evolution of corneal infections, their treatment requires rapid institution to limit the impact on vision and prevent complications such as scarring and corneal perforation. Given their rapid effects on microbial viability, light-based technologies seem particularly promising in this regard.


  • Open Access

    Editorial: Photonics-based diagnosis and treatment of infectious and inflammatory diseases

    by Leon G. Leanse, Weili Hong, Alessandra Nara de Souza Rastelli

    Editorial: Photonics-based diagnosis and treatment of infectious and inflammatory diseases


  • Open Access

    Editorial: Novel approaches to prevention, diagnosis, and treatment of bacterial and viral infections of clinical relevance

    by Leon G. Leanse, Claudia Maria Trombetta, George W. Carnell

    Editorial: Novel approaches to prevention, diagnosis, and treatment of bacterial and viral infections of clinical relevance

  • How can biophotonics help dentistry to avoid or minimize cross infection by SARS-CoV-2?

    by João Felipe Besegato, Priscila Borges Gobbo de Melo, Patrícia Eriko Tamae, Ana Paula Aparecida Raimundo Alves, Luis Felipe Rondón, Leon G. Leanse, Carolina dos Anjos, Heitor Hussni Casarin, Michelle Alexandra Chinelatti, Gisele Faria, et al.


  • Open Access

    Rationally designed mariner vectors for functional genomic analysis of Actinobacillus pleuropneumoniae and other Pasteurellaceae species by transposon-directed insertion-site sequencing (TraDIS)

    by Janine T. Bossé, Yanwen Li, Leon G. Leanse, Liqing Zhou, Roy R. Chaudhuri, Sarah E. Peters, Jinhong Wang, Gareth A. Maglennon, Matthew T. G. Holden, Duncan J. Maskell, et al.

    Comprehensive identification of conditionally essential genes requires efficient tools for generating high-density transposon libraries that, ideally, can be analysed using next-generation sequencing methods such as Transposon Directed Insertion-site Sequencing (TraDIS). The Himar1 (mariner) transposon is ideal for generating near-saturating mutant libraries, especially in AT-rich chromosomes, as the requirement for integration is a TA dinucleotide, and this transposon has been used for mutagenesis of a wide variety of bacteria. However, plasmids for mariner delivery do not necessarily work well in all bacteria. In particular, there are limited tools for functional genomic analysis of Pasteurellaceae species of major veterinary importance, such as swine and cattle pathogens, Actinobacillus pleuropneumoniae and Pasteurella multocida, respectively. Here, we developed plasmids, pTsodCPC9 and pTlacPC9 (differing only in the promoter driving expression of the transposase gene), that allow delivery of mariner into both these pathogens, but which should also be applicable to a wider range of bacteria. Using the pTlacPC9 vector, we have generated, for the first time, saturating mariner mutant libraries in both A. pleuropneumoniae and P. multocida that showed a near random distribution of insertions around the respective chromosomes as detected by TraDIS. A preliminary screen of 5000 mutants each identified 8 and 14 genes, respectively, that are required for growth under anaerobic conditions. Future high-throughput screening of the generated libraries will facilitate identification of mutants required for growth under different conditions, including in vivo, highlighting key virulence factors and pathways that can be exploited for development of novel therapeutics and vaccines.


  • Dual-wavelength photo-killing of methicillin-resistant Staphylococcus aureus

    by Leon G. Leanse, Xueping Sharon Goh, Ji-Xin Cheng, David C. Hooper, Tianhong Dai

    With the effectiveness of antimicrobials declining as antimicrobial resistance continues to threaten public health, we must look to alternative strategies for the treatment of infections. In this study, we investigated an innovative, drug-free, dual-wavelength irradiation approach that combines 2 wavelengths of light, 460 nm and 405 nm, against methicillin-resistant Staphylococcus aureus (MRSA). MRSA was initially irradiated with 460-nm light (90–360 J/cm 2 ) and subsequently irradiated with aliquots of 405-nm light (54–324 J/cm 2 ). For in vivo studies, mouse skin was abraded and infected with approximately 10 7 CFUs of MRSA and incubated for 3 hours before irradiating with 460 nm (360 J/cm 2 ) and 405 nm (342 J/cm 2 ). Naive mouse skin was also irradiated to investigate apoptosis. We found that staphyloxanthin, the carotenoid pigment in MRSA cells, promoted resistance to the antimicrobial effects of 405-nm light. In addition, we found that the photolytic effect of 460-nm light on staphyloxanthin attenuated resistance of MRSA to 405-nm light killing. Irradiation of 460 nm alone did not elicit any antimicrobial effect on MRSA. In a proof-of-principle mouse skin abrasion infection model, we observed significant killing of MRSA using the dual-wavelength irradiation approach. However, when either wavelength of light was administered alone, no significant decrease in bacterial viability was observed. Moreover, exposure of the dual-wavelength irradiation to naive mouse skin did not result in any visible apoptosis. In conclusion, a dual-wavelength irradiation strategy may offer an innovative, effective, and safe approach for the treatment of skin infections caused by MRSA.